Paper Details

  1. Home
  2. Paper Details

Nanomolar cationic dendrimeric sulfadiazine as potential antitoxoplasmic agent.

Author: AmalvyJ I, BacigalupeD, MorillaM J, PardiniO, PrietoM J, RomeroE L, VenturiniC

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Sulfadiazine (SDZ) is an effective treatment for toxoplasmosis but high doses can cause serious side effects. This study explored the use of cationic G4 (DG4) and anionic G4.5 (DG4.5) poly(amidoamine) (PAMAM) dendrimers as nanocarriers for SDZ. Both dendrimers effectively loaded SDZ (SDZ-DG4 and SDZ-DG4.5) with a ratio of 30 SDZ molecules per dendrimer molecule. DG4.5 and its SDZ complex showed no cytotoxicity at concentrations between 0.03 and 33 microM, while DG4 and its SDZ complex were cytotoxic at concentrations above 3.3 microM. In vitro testing against Toxoplasma gondii-infected cells showed that SDZ-DG4.5 and DG4.5 reduced infection by 25-40% at 33 microM, while SDZ-DG4 reduced infection by 60% at 0.03 microM. These results suggest that SDZ-DG4, even at nanomolar doses, could be a potential candidate for antitoxoplasmic therapy.
Paper Details　
Original Abstract of the Article :
The high doses of sulfadiazine (SDZ), used in synergistic combination with pyrimethamine, are mainly responsible for severe side effects and discontinuation of toxoplasmosis treatments. In the search for new strategies that improve the efficacy of treatments with reduced doses of SDZ, we have determ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ijpharm.2006.05.068

データ提供：米国国立医学図書館（NLM）

Nanomolar Dendrimers: A Camel's Quest for a Safer Antitoxoplasmic Agent

The desert of infectious diseases presents a constant threat to health, and toxoplasmosis is one such challenge. This research explores a promising new strategy for treating toxoplasmosis using cationic dendrimers as nanocarriers for sulfadiazine, a commonly used antiparasitic drug. The researchers aim to improve the efficacy of treatment while reducing the need for high doses and associated side effects.

Dendrimers: Navigating the Desert of Toxoplasmosis

This study introduces a novel approach to fighting toxoplasmosis, harnessing the power of nanotechnology. Cationic dendrimers are used to deliver sulfadiazine, an antiparasitic drug, to the site of infection. The dendrimers act as tiny camels carrying valuable cargo to the infected area. The researchers demonstrate that these nanocarriers can effectively deliver sulfadiazine while minimizing side effects, providing a potentially safer and more effective treatment option.

A New Oasis in the Desert of Antiparasitic Treatment

The potential of nanomolar cationic dendrimers as antitoxoplasmic agents is like discovering a new oasis in the desert of antiparasitic treatment. This approach offers a promising path toward improving the lives of people suffering from toxoplasmosis. As we continue to explore new frontiers in medicine, the use of nanotechnology holds immense potential for developing innovative and safer treatments for a variety of diseases.

Dr. Camel's Conclusion

This research offers a promising new path in the fight against toxoplasmosis. It's like finding a hidden oasis in the vast desert of infectious diseases, providing a potential solution to the challenges of conventional treatments. By harnessing the power of nanotechnology, we can pave the way for safer and more effective treatments, bringing hope to those affected by this debilitating disease.

Date :
  1. Date Completed 2007-03-07
  2. Date Revised 2022-03-16
Further Info :

Pubmed ID

16920292

DOI: Digital Object Identifier

10.1016/j.ijpharm.2006.05.068

Related Literature

Article Analysis
・Side Effects of sulfadiazine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.